Genetics and the potential for predictive tests in adverse drug reactions

Chemical Immunology and Allergy

Volumn 97, Issue , 2012, Pages 18-31

  Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ALLOPURINOL; AMINOPENICILLIN; CARBAMAZEPINE; COTRIMOXAZOLE; FEPRAZONE; FLUCLOXACILLIN; GOLD; HLA A ANTIGEN; IODINE; LAMOTRIGINE; LAPATINIB; LUMIRACOXIB; NEVIRAPINE; OXICAM DERIVATIVE; PHENYTOIN; SULFAMETHOXAZOLE; XIMELAGATRAN;

ARTICLE; DISEASE PREDISPOSITION; DRUG HYPERSENSITIVITY; FIXED DRUG ERUPTION; GENETIC PREDISPOSITION; HEREDITY; HUMAN; IMMUNE SYSTEM; LIVER INJURY; MACULOPAPULAR RASH; MOLECULAR TYPING; PHENOTYPE; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS;

ALLOPURINOL; ANTI-BACTERIAL AGENTS; ANTI-HIV AGENTS; ANTICONVULSANTS; ANTIMETABOLITES; BIOLOGICAL MARKERS; CARBAMAZEPINE; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; DRUG-INDUCED LIVER INJURY; EPIDERMAL NECROLYSIS, TOXIC; GENOME-WIDE ASSOCIATION STUDY; HLA ANTIGENS; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; IMMUNE SYSTEM; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; STEVENS-JOHNSON SYNDROME;

EID: 84926079539     PISSN: 16602242     EISSN: 16622898     Source Type: Book Series    
DOI: 10.1159/000335613     Document Type: Article

References (86)

1. Pirmohamed M, James S, Meakin S, et al: Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ 2004; 329:15-19.
2. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M: Adverse drug reactions in hospital in-patients: a prospective analysis of 3,695 patient-episodes. PLoS One 2009;4:e4439.
3. Davies EC, Green CF, Mottram DR, Pirmohamed M: Adverse drug reactions in hospitals: a narrative review. Curr Drug Saf 2007;2:79-87.
4. Lazarou J, Pomeranz BH, Corey PN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 1998;279:1200-1205.
5. Rawlins MD, Thompson JW: Mechanisms of adverse drug reactions; in Davies DM, (ed): Textbook of Adverse Drug Reactions. Oxford, Oxford University Press, 1991, pp 18-45.
6. Wadelius M, Pirmohamed M: Pharmacogenetics of warfarin: current status and future challenges. Pharma cogenomics J 2007;7:99-111.
7. Alfirevic A, Pirmohamed M: Drug-induced hypersensitivity reactions and pharmacogenomics: past, present and future. Pharmacogenomics 2010;11: 497-499.
8. Voight BF, Scott LJ, Steinthorsdottir V, et al: Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42: 579-589.
9. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. New Engl J Med 1994;331: 1272-1285.
10. Rawlins MD: Pharmacovigilance: paradise lost, regained or postponed? J R Coll Physicians Lond 1995;29:41-49.
11. Pirmohamed M, Aithal GP, Behr E, Daly A, Roden D: The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther 2011;89:784-785.
12. Pirmohamed M, Friedmann PS, Molokhia M, et al: Phenotype standardization for immune-mediated drug-induced skin injury. Clin Pharmacol Ther 2011;89:896-901.
13. Hindorff LA, Sethupathy P, Junkins HA, et al: Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA 2009;106:9362-9367.
14. Daly AK: Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010;11:241-246.
15. Alfirevic A, Pirmohamed M: Drug induced hypersensitivity and the HLA complex. Pharmaceuticals 2011;4:69-90.
16. Hetherington S, Hughes AR, Mosteller M, et al: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002;359: 1121-1122.
17. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M: Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004;14:335-342.
18. Mallal S, Nolan D, Witt C, et al: Association between presence of HLA-B*5701, HLA-DR7, and HLADQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359: 727-732.
19. Bodmer W, Bonilla C: Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 2008;40:695-701.
20. Pirmohamed M, Park BK: Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22:298-305.
21. Green VJ, Pirmohamed M, Kitteringham NR, et al: Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity. Biochem Pharmacol 1995;50:1353-1359.
22. Sullivan JR, Shear NH: The drug hypersensitivity syndrome: what is the pathogenesis? Arch Dermatol 2001;137:357-364.
23. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK: The danger hypothesis -potential role in idiosyncratic drug reactions. Toxicology 2002;181-182: 55-63.
24. Naisbitt DJ, Britschgi M, Wong G, et al: Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003;63:732-741.
25. Naisbitt DJ, Farrell J, Wong G, et al: Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003;111:1393-1403.
26. Pichler WJ, Adam J, Daubner B, Gentinetta T, Keller M, Yerly D: Drug hypersensitivity reactions: pathomechanism and clinical symptoms. Med Clin North Am 2010;94:645-664, xv.
27. Easterbrook PJ, Waters A, Murad S, et al: Epidemiological risk factors for hypersensitivity reactions to abacavir. HIV Med 2003;4:321-324.
28. Phillips EJ, Sullivan JR, Knowles SR, Shear NH: Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 2002;16:2223-2225.
29. Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG: Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics 2010;28:1025-1039.
30. Nieves Calatrava D, Calle-Martin Ode L, Iribarren-Loyarte JA, et al: Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. Enferm Infecc Microbiol Clin 2010;28:590-595.
31. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE: The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 2008;22:2025-2033.
32. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S: Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006;43:99-102.
33. Waters LJ, Mandalia S, Gazzard B, Nelson M: Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 2007;21:2533-2534.
34. Zucman D, Truchis P, Majerholc C, Stegman S, Caillat-Zucman S: Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J Acquir Immune Defic Syndr 2007; 45:1-3.
35. Saag M, Balu R, Phillips E, et al: High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis 2008; 46:1111-1118.
36. Mallal S, Phillips E, Carosi G, et al: HLA-B*5701 screening for hypersensitivity to abacavir. New Engl J Med 2008;358:568-579.
37. Colombo S, Rauch A, Rotger M, et al: The HCP5 single-nucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J Infect Dis 2008;198:864-867.
38. Dello Russo C, Lisi L, Lofaro A, et al: Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. Pharmacogenomics 2011;12:567-576.
39. Kostenko L, Kjer-Nielsen L, Nicholson I, et al: Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. Tissue Antigens 2011;78:11-20.
40. Chessman D, Kostenko L, Lethborg T, et al: Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008;28: 822-832.
41. Chung WH, Hung SI, Hong HS, et al: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428:486.
42. Hung SI, Chung WH, Jee SH, et al: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16: 297-306.
43. Man CB, Kwan P, Baum L, et al: Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48:1015-1018.
44. Locharernkul C, Loplumlert J, Limotai C, et al: Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008;49: 2087-2091.
45. Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al: Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010; 51:926-930.
46. Ding WY, Lee CK, Choon SE: Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2010;49:834-841.
47. Mehta TY, Prajapati LM, Mittal B, et al: Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009;75:579-582.
48. Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006;7:813-818.
49. Lonjou C, Borot N, Sekula P, et al: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008;18:99-107.
50. Lonjou C, Thomas L, Borot N, et al: A marker for Stevens-Johnson syndrome. . .: ethnicity matters. Pharmacogenomics J 2006;6:265-268.
51. Ikeda H, Takahashi Y, Yamazaki E, et al: HLA class I markers in Japanese patients with carbamazepineinduced cutaneous adverse reactions. Epilepsia 2010; 51:297-300.
52. Kaniwa N, Saito Y, Aihara M, et al: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9:1617-1622.
53. Romano A, Gueant-Rodriguez RM, Viola M, Gaeta F, Caruso C, Gueant JL: Cross-reactivity among drugs: clinical problems. Toxicology 2005;209: 169-179.
54. Chen YC, Chu CY, Hsiao CH: Oxcarbazepineinduced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J Eur Acad Dermatol Venereol 2009;23:702-703.
55. Chen P, Lin JJ, Lu CS, et al: Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. New Engl J Med 2011;364:1126-1133.
56. McCormack M, Alfirevic A, Bourgeois S, et al: HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. New Engl J Med 2011;364:1134-1143.
57. Hung SI, Chung WH, Liou LB, et al: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134-4139.
58. Tassaneeyakul W, Jantararoungtong T, Chen P, et al: Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009;19:704-709.
59. Kang HR, Jee YK, Kim YS, et al: Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011;21:303-307.
60. Lee MH, Stocker SL, Anderson J, et al: Initiating allopurinol therapy: do we need to know the patient's HLA status? Intern Med J 2011, Epub ahead of print.
61. Shen Y, Nicoletti P, Floratos A, et al: Genome-wide association study of serious blistering skin rash caused by drugs. Pharmacogenomics J 2011, Epub ahead of print.
62. Daly AK, Donaldson PT, Bhatnagar P, et al: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816-819.
63. Lucena MI, Molokhia M, Shen Y, et al: Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011;141:338-347.
64. Spraggs CF, Budde LR, Briley LP, et al: HLADQA1* 02:01 is a major risk factor for lapatinibinduced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011;29:667-673.
65. Singer JB, Lewitzky S, Leroy E, et al: A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010;42: 711-714.
66. Kindmark A, Jawaid A, Harbron CG, et al: Genomewide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008;8:186-195.
67. Pirmohamed M: Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles. Clin Pharmacol Ther 2010;88:862-866.
68. Ozeki T, Mushiroda T, Yowang A, et al: Genomewide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011;20:1034-1041.
69. Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R: Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987;123: 1171-1173.
70. Roujeau JC, Bracq C, Huyn NT, Chaussalet E, Raffin C, Duedari N: HLA phenotypes and bullous cutaneous reactions to drugs. Tissue Antigens 1986;28: 251-254.
71. Hughes AR, Mosteller M, Bansal AT, et al: Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004;5:203-211.
72. Hughes AR, Brothers CH, Mosteller M, Spreen WR, Burns DK: Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example. Pharmacogenomics 2009;10:225-233.
73. Romano A, De Santis A, Romito A, et al: Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann Allergy Asthma Immunol 1998;80:433-437.
74. Martin AM, Nolan D, James I, et al: Predisposition to nevirapine hypersensitivity associated with HLADRB1* 0101 and abrogated by low CD4 T-cell counts. AIDS 2005;19:97-99.
75. Vitezica ZG, Milpied B, Lonjou C, et al: HLADRB1* 01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008; 22:540-541.
76. Littera R, Carcassi C, Masala A, et al: HLAdependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006;20:1621-1626.
77. Gatanaga H, Yazaki H, Tanuma J, et al: HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007;21:264-265.
78. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al: HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 2009;19:139-146.
79. Likanonsakul S, Rattanatham T, Feangvad S, et al: HLA-Cw*04 allele associated with nevirapineinduced rash in HIV-infected Thai patients. AIDS Res Ther 2009;6:22.
80. Kim SH, Choi JH, Lee KW, et al: The human leucocyte antigen- DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy 2005;35: 339-344.
81. Palikhe NS, Kim SH, Park HS: What do we know about the genetics of aspirin intolerance? J Clin Pharm Ther 2008;33:465-472.
82. Torres MJ, Mayorga C, Cornejo-Garcia JA, et al: Monitoring non-immediate allergic reactions to iodine contrast media. Clin Exp Immunol 2008; 152:233-238.
83. Rodriguez-Perez M, Gonzalez-Dominguez J, Mataran L, Garcia-Perez S, Salvatierra D: Association of HLA-DR5 with mucocutaneous lesions in patients with rheumatoid arthritis receiving gold sodium thiomalate. J Rheumatol 1994;21:41-43.
84. Kazeem GR, Cox C, Aponte J, et al: High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics 2009;19:661-665.
85. Ozkaya-Bayazit E, Akar U: Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype. J Am Acad Dermatol 2001;45:712-717.
86. Pellicano R, Lomuto M, Ciavarella G, Di Giorgio G, Gasparini P: Fixed drug eruptions with feprazone are linked to HLA-B22. J Am Acad Dermatol 1997; 36:782-784.